Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shinya Watanabe

Showing results (341-350 of 364) with videos related to

Pageof 37
Sort By:
Cancer Immunology, Immunotherapy : CII|December 7, 2019
Tumor mutation burden and immunological, genomic, and clinicopathological factors as biomarkers for checkpoint inhibitor treatment of patients with non-small-cell lung cancerYuki Ozaki, Satoshi Muto, Hironori Takagi, et al.
Nature Communications|June 12, 2020
Development of CRISPR-Cas13a-based antimicrobials capable of sequence-specific killing of target bacteriaKotaro Kiga, Xin-Ee Tan, Rodrigo Ibarra-Chávez, et al.
Scientific Reports|December 9, 2022
Biological properties of Staphylococcus virus ΦSA012 for phage therapyJumpei Fujiki, Tomohiro Nakamura, Keisuke Nakamura, et al.
Cancer Diagnosis & Prognosis|November 6, 2024
Risk Classification of Patients With Advanced Urothelial Carcinoma Treated With Enfortumab VedotinGaku Ishikawa, Yuto Matsushita, Yuichi Kitagawa, et al.
Frontiers in Microbiology|April 4, 2022
The Association Between Onset of Staphylococcal Non-menstrual Toxic Shock Syndrome With Inducibility of Toxic Shock Syndrome Toxin-1 ProductionYusuke Taki, Shinya Watanabe, Yusuke Sato'o, et al.
FEBS Letters|May 16, 2012
Expression screening of 17q12-21 amplicon reveals GRB7 as an ERBB2-dependent oncogeneMakoto Saito, Yukiko Kato, Emi Ito, et al.
Anticancer Research|May 27, 2026
Development of a Prognostic Model for Patients Aged ≤65 Years With Metastatic Renal Cell CarcinomaYuya Oishi, Yuto Matsushita, Shinya Watanabe, et al.
Oncology Letters|February 12, 2021
Tumor β-catenin expression is associated with immune evasion in non-small cell lung cancer with high tumor mutation burdenSatoshi Muto, Yuki Ozaki, Hikaru Yamaguchi, et al.
Oncology Letters|February 14, 2018
Family with sequence similarity 83, member B is a predictor of poor prognosis and a potential therapeutic target for lung adenocarcinoma expressing wild-type epidermal growth factor receptorTakumi Yamaura, Junji Ezaki, Naoyuki Okabe, et al.
Japanese Journal of Clinical Oncology|May 17, 2026
Development of a prognostic model for elderly patients with metastatic clear cell renal cell carcinoma treated with first-line immuno-oncology combination therapyShinya Watanabe, Yuto Matsushita, Yuya Oishi, et al.
Pageof 37

Showing results (341-350 of 364) with videos related to

Sort By:
Pageof 37
Cancer Immunology, Immunotherapy : CII|December 7, 2019
Tumor mutation burden and immunological, genomic, and clinicopathological factors as biomarkers for checkpoint inhibitor treatment of patients with non-small-cell lung cancerYuki Ozaki, Satoshi Muto, Hironori Takagi, et al.
Nature Communications|June 12, 2020
Development of CRISPR-Cas13a-based antimicrobials capable of sequence-specific killing of target bacteriaKotaro Kiga, Xin-Ee Tan, Rodrigo Ibarra-Chávez, et al.
Scientific Reports|December 9, 2022
Biological properties of Staphylococcus virus ΦSA012 for phage therapyJumpei Fujiki, Tomohiro Nakamura, Keisuke Nakamura, et al.
Cancer Diagnosis & Prognosis|November 6, 2024
Risk Classification of Patients With Advanced Urothelial Carcinoma Treated With Enfortumab VedotinGaku Ishikawa, Yuto Matsushita, Yuichi Kitagawa, et al.
Frontiers in Microbiology|April 4, 2022
The Association Between Onset of Staphylococcal Non-menstrual Toxic Shock Syndrome With Inducibility of Toxic Shock Syndrome Toxin-1 ProductionYusuke Taki, Shinya Watanabe, Yusuke Sato'o, et al.
FEBS Letters|May 16, 2012
Expression screening of 17q12-21 amplicon reveals GRB7 as an ERBB2-dependent oncogeneMakoto Saito, Yukiko Kato, Emi Ito, et al.
Anticancer Research|May 27, 2026
Development of a Prognostic Model for Patients Aged ≤65 Years With Metastatic Renal Cell CarcinomaYuya Oishi, Yuto Matsushita, Shinya Watanabe, et al.
Oncology Letters|February 12, 2021
Tumor β-catenin expression is associated with immune evasion in non-small cell lung cancer with high tumor mutation burdenSatoshi Muto, Yuki Ozaki, Hikaru Yamaguchi, et al.
Oncology Letters|February 14, 2018
Family with sequence similarity 83, member B is a predictor of poor prognosis and a potential therapeutic target for lung adenocarcinoma expressing wild-type epidermal growth factor receptorTakumi Yamaura, Junji Ezaki, Naoyuki Okabe, et al.
Japanese Journal of Clinical Oncology|May 17, 2026
Development of a prognostic model for elderly patients with metastatic clear cell renal cell carcinoma treated with first-line immuno-oncology combination therapyShinya Watanabe, Yuto Matsushita, Yuya Oishi, et al.
Pageof 37